| Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532, 2015 | 6249 | 2015 |
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial A Hauschild, JJ Grob, LV Demidov, T Jouary, R Gutzmer, M Millward, ... The Lancet 380 (9839), 358-365, 2012 | 3542 | 2012 |
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ... Science 350 (6257), 207-211, 2015 | 2786 | 2015 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1839 | 2018 |
| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 1814 | 2020 |
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015 | 1779 | 2015 |
| The human tumor microbiome is composed of tumor type–specific intracellular bacteria D Nejman, I Livyatan, G Fuks, N Gavert, Y Zwang, LT Geller, ... Science 368 (6494), 973-980, 2020 | 1465 | 2020 |
| LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells A Brand, K Singer, GE Koehl, M Kolitzus, G Schoenhammer, A Thiel, ... Cell metabolism 24 (5), 657-671, 2016 | 1414 | 2016 |
| Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet 390 (10105), 1853-1862, 2017 | 1316 | 2017 |
| Defining ‘T cell exhaustion’ CU Blank, WN Haining, W Held, PG Hogan, A Kallies, E Lugli, RC Lynn, ... Nature Reviews Immunology 19 (11), 665-674, 2019 | 1157 | 2019 |
| Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet Oncology 20 (9), 1239-1251, 2019 | 1074 | 2019 |
| PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells C Blank, I Brown, AC Peterson, M Spiotto, Y Iwai, T Honjo, TF Gajewski Cancer research 64 (3), 1140-1145, 2004 | 1038 | 2004 |
| Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ... Nature 508 (7494), 118-122, 2014 | 906 | 2014 |
| Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma H Li, AM van der Leun, I Yofe, Y Lubling, D Gelbard-Solodkin, ... Cell 176 (4), 775-789. e18, 2019 | 893 | 2019 |
| Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy C Blank, TF Gajewski, A Mackensen Cancer Immunology, Immunotherapy 54, 307-314, 2005 | 828 | 2005 |
| The “cancer immunogram” CU Blank, JB Haanen, A Ribas, TN Schumacher Science 352 (6286), 658-660, 2016 | 804 | 2016 |
| Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma CU Blank, EA Rozeman, LF Fanchi, K Sikorska, B van de Wiel, ... Nature medicine 24 (11), 1655-1661, 2018 | 769 | 2018 |
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study PA Ascierto, D Schadendorf, C Berking, SS Agarwala, CML van Herpen, ... The lancet oncology 14 (3), 249-256, 2013 | 764 | 2013 |
| Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ... Nature medicine 25 (6), 920-928, 2019 | 754 | 2019 |
| Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ... Nature communications 5 (1), 5712, 2014 | 717 | 2014 |
